Japan Patent Allowance for RECCE Anti-Infectives

Key points

• Japan Patent Office grants allowance for Recce's Anti-Infectives Patent Family 4
• Patent claims cover RECCE® 327 and RECCE® 529 for treatment of bacterial, viral, and other infections
• Provides global patent protection, including Australia, Canada, and Israel

Full summary

Recce Pharmaceuticals Ltd, the company developing a New Class of Synthetic Anti-Infectives, has announced the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 covering its RECCE® anti-infectives. The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including the process for preparation, use for the treatment of various diseases, and administration methods. This is the fourth Family 4 patent, alongside Australia, Canada, and Israel, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review or allowance. Japan is the third-largest pharmaceutical market globally, and the antibiotic resistance market in Japan is expected to reach a projected revenue of US$ 411.3 million by 2030, with a compound annual growth rate of 6.1% from 2024 to 2030. Recce Pharmaceuticals' Chief Executive Officer, James Graham, stated that the Japan Patent Office's formal recognition of Recce's New Class of Anti-Infectives underscores the company's commitment to addressing critical unmet medical needs with innovative therapies and positions it well to deliver meaningful solutions for patients worldwide.